¡Tres nuevas ofertas públicas esta semana! ¡La empresa líder en almacenamiento nacional debutará en las acciones A!

据目前安排，若无变化本周（3月30日到4月3日）有3只新股申购。 Among them, 1 from the Science and Technology Innovation Board, 1 from the Growth Enterprise Board, and 1 from the Beijing Stock Exchange.

本周3股打新

截至发稿，本周网上发行2只新股披露发行价。 As of the time of writing, the online offering prices for 2 new shares have been disclosed this week. 科创板新股有研复材发行价为6.41元，发行市盈率58.09倍，行业最近一个月平均动态市盈率33.62倍。 The Science and Technology Innovation Board new share, Youyan Composite Materials, has an issuance price of 6.41 yuan, with an issuance price-earnings ratio of 58.09 times, and the average dynamic price-earnings ratio of the industry in the last month is 33.62 times. 北交所新股赛英电子发行价为28元，发行市盈率13.79倍，行业最近一个月平均动态市盈率25.82倍。 The Beijing Stock Exchange new share, Saiying Electronics, has an issuance price of 28 yuan, with an issuance price-earnings ratio of 13.79 times, and the average dynamic price-earnings ratio of the industry in the last month is 25.82 times.

3月30日启动申购的有研复材本次网上发行股票数量为1826万股，网上发行申购上限为1.8万股，顶格申购需配沪市市值18万元。 Youyan Composite Materials, which starts subscription on March 30, has a total of 18.26 million shares for online issuance, with a subscription limit of 18,000 shares, and the maximum subscription requires a Shanghai Stock Exchange market value of 180,000 yuan.

有研复材是国务院国资委直属央企中国有研所属二级产业化公司，专注于金属复合材料及制品、特种有色金属合金制品研发、生产和销售。 Youyan Composite Materials is a second-level industrialization company affiliated with China Research, a central enterprise directly under the State-owned Assets Supervision and Administration Commission of the State Council, focusing on the research and development, production, and sales of metal composite materials and products, as well as special non-ferrous metal alloy products. 公司核心产品包括金属基复合材料及制品、双金属复合材料及制品、特种铝合金和特种铜合金制品等。 The company’s core products include metal matrix composite materials and products, bimetallic composite materials and products, special aluminum alloys, and special copper alloy products.

有研复材起源于1992年成立的国家复合材料工程中心，是国内最早从事金属基复合材料研制的单位之一，建成国内第一条年产400吨的铝基复合材料粉末冶金生产线，是国内首家实现金属基复合材料大规模工程应用的企业，主要产品应用于航空航天、军工电子、智能终端等多个重点领域。 Youyan Composite Materials originated from the National Composite Materials Engineering Center established in 1992 and is one of the earliest units in China engaged in the research and development of metal matrix composites. It built the first aluminum-based composite materials powder metallurgy production line with an annual output of 400 tons in China and is the first enterprise in China to achieve large-scale engineering application of metal matrix composites. Its main products are applied in several key areas such as aerospace, military electronics, and smart terminals. 本次IPO，有研复材募资总额8.36亿元。 In this IPO, Youyan Composite Materials aims to raise a total of 836 million yuan.

4月3日启动申购的大普微本次网上发行股票数量为697.9万股，网上发行申购上限为0.65万股，顶格申购需配深市市值6.5万元。 Dapu Micro, which starts subscription on April 3, has a total of 6.979 million shares for online issuance, with a subscription limit of 6,500 shares, and the maximum subscription requires a Shenzhen Stock Exchange market value of 65,000 yuan.

大普微深度聚焦数据中心存储场景，是国内极少数具备数据中心企业级“主控芯片＋固件算法＋模组”全栈自研能力并实现批量出货的半导体存储产品提供商。 Dapu Micro deeply focuses on data center storage scenarios and is one of the few domestic semiconductor storage product providers with full-stack self-research capabilities of “main control chip + firmware algorithm + module” for enterprise-level data centers and has achieved bulk shipments. 根据IDC数据，最近三年国内企业级SSD市场中，大普微占有率稳居市场前列，国际厂商仍占据主导地位。 According to IDC data, in the domestic enterprise-grade SSD market over the past three years, Dapu Micro has maintained a leading market share, while international manufacturers still dominate the market. 2025年，大普微已通过Nvidia、xAI两家全球AI头部前沿公司测试导入，后续有望逐步放量，形成了明显的客户资源优势。 By 2025, Dapu Micro has been tested and introduced by two global AI leading companies, Nvidia and xAI, and is expected to gradually ramp up production, forming a significant advantage in customer resources. 本次IPO，大普微拟募资18.78亿元。 In this IPO, Dapu Micro plans to raise 1.878 billion yuan.

5公司IPO上会

值得注意的是，截至目前本周（3月30日到4月3日）将有5家IPO首发上会，为拟闯关创业板IPO的欣兴工具，科创板IPO的泰诺麦博，北交所IPO的永励精密、百英生物和新睿电子。 It is worth noting that as of now, this week (from March 30 to April 3), there will be 5 companies’ IPOs up for review, including Xinxing Tools, which is attempting to go public on the Growth Enterprise Board, Tianomaibo on the Science and Technology Innovation Board, and Yongli Precision, Baiying Biotechnology, and Xinrui Electronics on the Beijing Stock Exchange.

3月31日创业板IPO上会的欣兴工具是国内领先的孔加工刀具生产企业，自设立以来始终聚焦于孔加工刀具中钻削刀具产品的研发、生产和销售业务，形成了环形钻削系列产品、实心钻削系列产品及相关配套产品。 Xinxing Tools, which is scheduled for IPO review on the Growth Enterprise Board on March 31, is a leading domestic manufacturer of hole processing tools. Since its establishment, it has focused on the research and development, production, and sales of drilling tools in the hole processing tool sector, forming a series of annular drilling products, solid drilling products, and related supporting products. 公司产品广泛应用于钢结构工程、轨道交通、造船业、能源装备、机械制造、石油工程等工程制造及数控加工领域。 The company’s products are widely used in engineering manufacturing and CNC processing fields such as steel structure engineering, rail transit, shipbuilding, energy equipment, machinery manufacturing, and petroleum engineering. 本次IPO，欣兴工具拟募资5.6亿元。 In this IPO, Xinxing Tools plans to raise 560 million yuan.

4月3日科创板IPO上会的泰诺麦博是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。 Tianomaibo, which is scheduled for IPO review on the Science and Technology Innovation Board on April 3, is an innovative biopharmaceutical company focused on alternative therapies for blood products in the global market. 公司核心产品斯泰度塔单抗注射液于2025年2月在中国获批上市，为全球同类首创的重组抗破伤风毒素单克隆抗体药物，被中国CDE认定为突破性治疗药物并纳入优先审评程序、被美国FDA纳入快速通道资格，在破伤风预防领域具有全球领先的革新性意义。 The company’s core product, Staitouta monoclonal antibody injection, was approved for listing in China in February 2025 and is the world’s first recombinant monoclonal antibody drug against tetanus toxin. It has been recognized as a breakthrough therapy by the Chinese CDE and included in the priority review process, and has been granted fast track designation by the US FDA, representing a global leading innovative significance in the field of tetanus prevention. 公司另一核心产品“重组抗呼吸道合胞病毒全人源单克隆抗体TNM001”以非高危及高危婴儿为适应症人群已递交NDA并获受理，同时已纳入优先审评程序。 The company’s other core product, “Recombinant full-human monoclonal antibody TNM001 against respiratory syncytial virus,” has submitted an NDA for non-high-risk and high-risk infants and has been accepted, and has also been included in the priority review process. 本次IPO，泰诺麦博拟募资15亿元。 In this IPO, Tianomaibo plans to raise 1.5 billion yuan.

打新日历

3月30日

有研复材(688811)

赛英电子(920181)

4月3日

大普微(301666)

校对：盘达